GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
377.50
-0.15 (-0.04%)
At close: Jun 5, 2025
211.96%
Market Cap 120.22B
Revenue (ttm) 61.15B
Net Income (ttm) 8.10B
Shares Out 318.47M
EPS (ttm) 25.43
PE Ratio 14.85
Forward PE n/a
Dividend 10.00 (2.65%)
Ex-Dividend Date Apr 18, 2025
Volume 315,711
Average Volume 475,668
Open 380.00
Previous Close 377.65
Day's Range 375.30 - 385.00
52-Week Range 118.00 - 481.00
Beta 0.38
RSI 47.10
Earnings Date Aug 22, 2025

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc. [Read more]

Industry Pharmaceuticals
Sector Healthcare
Founded 2001
Employees 1,700
Stock Exchange Pakistan Stock Exchange
Ticker Symbol GLAXO
Full Company Profile

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.

Financial Statements

News

There is no news available yet.